1. Introduction
===============

Breast cancer is the most common malignant tumor and cause of cancer-related death among women, representing a major health problem worldwide.^\[[@R1]\]^ In Portugal, it has the highest incidence and mortality rates among female diseases,^\[[@R2]\]^ and is the second most common malignant tumor in Indian women^\[[@R3]\]^ and the third most common malignant tumor in Korean women.^\[[@R4]\]^ Some studies have indicated that alcohol consumption, tobacco, and particular food habits, especially high fat intake, are important risk factors for breast cancer.^\[[@R5],[@R6]\]^ In addition, previous studies indicated that cancer is related to the combined influences of genetic factors, environmental factors, and lifestyle. Hence, genetic polymorphism studies have become important in identifying the combined factors that may affect individual breast cancer susceptibility.^\[[@R7],[@R8]\]^

Glutathione S-transferases (GSTs) are a family of multifunctional enzymes involved in the metabolism of a variety of xenobiotic compounds, including mammary carcinogens such as polycyclic aromatic hydrocarbons (PAHs).^\[[@R9]--[@R11]\]^ GST~S~ have the capacity to detoxify the reactive product of metabolisms of PAHs, thereby preventing their interaction with DNA. According to their primary structure, the *GST* family is divided into 7 categories of genes in human.^\[[@R12]\]^ In this meta-analysis, we studied glutathione S-transferase M1 (*GSTM1*) and glutathione S-transferase T1 (*GSTT1*) polymorphisms for breast cancer susceptibility. *GSTM1* and *GSTT1* genes are located on chromosome 1 (1p13.3) and chromosome 22 (22q11.2), respectively.^\[[@R13]\]^ In humans, *GSTM1* is expressed in various tissues such as the liver, stomach, brain, and breast, while *GSTT1* is mainly expressed in the liver and erythrocytes.^\[[@R14]\]^ Polymorphisms in both *GSTM1* and *GSTT1* result in gene deletions (null genotype), resulting in loss of expression and enzyme activity loss.^\[[@R15],[@R16]\]^ Lack of enzymatic activity may lead to the occurrence of cancer.

In 1998, the first study of the association between the combined effects of *GSTM1* and *GSTT1* polymorphisms on breast cancer risk was reported.^\[[@R17]\]^ Subsequently, 34 articles^\[[@R12]--[@R14],[@R17]--[@R47]\]^ on this issue have been published. However, the results have been controversial and inconsistent. Some studies found no significant association; others reported an increased breast cancer risk. Several previously published meta-analyses did not assess the combined effects of *GSTM1* and *GSTT1* polymorphisms with breast cancer risk.^\[[@R48]--[@R55]\]^ Hence, to address this association, a meta-analysis was performed to explore whether there was an association between the combined effects of *GSTM1* and *GSTT1* polymorphisms on breast cancer risk.

2. Materials and methods
========================

2.1. Search strategy
--------------------

PubMed, Embase, China National Knowledge Infrastructure (CNKI), and Wan Fang (WF) databases were searched (the last search was conducted on February 22, 2018). Two authors identified relevant studies using the following search strategy: breast and (glutathione S-transferase M1 OR *GSTM1*) and (glutathione S-transferase T1 or *GSTT1*) and (polymorph∗ or mutation∗ or variant∗ or genotype∗). There were no restrictions on language in the meta-analysis. Additional studies were identified through a search of references of original studies or review articles on this topic and through personal contact with the authors if necessary.

2.2. Inclusion and exclusion criteria
-------------------------------------

The studies were included if they met the following criteria:

1.  case--control, cohort, or nested case--control study;

2.  the diagnosis of breast cancer cases was confirmed pathologically and controls were confirmed to be free of breast cancer;

3.  complete data was supplied to calculate ORs and the corresponding 95% confidence intervals (CIs).

4.  Studies were excluded if they met the following criteria:

5.  duplicate data or incomplete data,

6.  only case studies, and

7.  meta-analyses, letters, reviews, conference abstracts, and case reports.

2.3. Data extraction
--------------------

Data were extracted independently by 2 authors. Any potential disagreement was adjudicated by a third investigator if required. The following data was collected from studies that met inclusion criteria: the surname of the first author, publication year, country, race, source of cases, source of controls, type of controls, matching, material used for assessment of genotype, sample size of case and control, and genotype frequencies of the combined effects of *GSTM1* present/null and *GSTT1* present/null polymorphisms.

2.4. Quality score assessment
-----------------------------

The 2 authors assessed independently assessed the quality of the studies. The quality assessment criteria were modified from previous meta-analyses of molecular association studies.^\[[@R56],[@R57]\]^ Total scores ranging from 0 (worst) to 19 (best) were used to assess the quality of studies (Table [1](#T1){ref-type="table"}). Low-quality studies were considered when scores were ≤11, while scores of \>11 were considered to be of high quality. Inconsistent scores were adjudicated by a third author.

###### 

Scale for quality assessment of molecular association studies of breast cancer.
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2.5. Statistical analysis
-------------------------

Pooled the crude odds ratios (ORs) and 95% CIs were calculated by Z-test and *P* \<.05 was considered to be statistically significant. The combined genotypes of *GSTM1* and *GSTT1* were analyzed using the following 6 genetic models: *GSTM1* null/*GSTT1* null (*− −*) versus *GSTM1* present/*GSTT1* present (+ +), *GSTM1* present/*GSTT1* null (+ *−*) versus + +, *GSTM1* null/*GSTT1* present (*−* +) versus + +, (+ *−*) + (*−* +) versus + +, (− −) + (+ *−*) + (*−* +) versus + +, and *− −* versus (+ +) + (+ *−*) + (*−* +). *− −* represented *GSTM1* null/*GSTT1* null, + + represented *GSTM1* present/*GSTT1* present, + *−* represented *GSTM1* present/*GSTT1* null, and *−* + represented *GSTM1* null/*GSTT1* present. Heterogeneity among studies was assessed by *Q* test and *I*^2^ value (significant heterogeneity was considered when *P* \<.10 and *I*^*2*^ \> 50%).^\[[@R58]\]^ Pooled ORs were calculated using a fixed-effects model^\[[@R59]\]^ when the heterogeneity was not significant, otherwise, a random-effects model was used.^\[[@R60]\]^ However, the included studies cannot be pooled into together when *I*^2^ value \>75%. Subgroup analyses were performed by ethnicity, source of control, matching, and menopausal status. We carried out a sensitivity analysis to assess the stability by the following methods:

1.  a single study was excluded, 1 at a time,

2.  the studies of sample size \<200 were excluded,

3.  low-quality studies were excluded, and

4.  we used a dataset that comprised only high-quality studies, matching studies, and genotyping performed blindly or with quality control.^\[[@R61]\]^

In addition, we applied a meta-regression analysis to explore the sources of heterogeneity. Moreover, publication bias was detected using the Begg funnel plot^\[[@R62]\]^ and Egger regression asymmetry test (statistical significance was considered when *P* \<.05).^\[[@R63]\]^ If there was publication bias, a nonparametric "trim and fill" method was used to impute missing studies.^\[[@R64]\]^ Last, a false-positive report probability (FPRP) test was applied to assess significant results. We preset a FPRP value of 0.2 for noteworthiness and set a prior probability of 0.001 to detect an OR of 1.50 for the combined genotypes with an increased risk. Noteworthy associations were considered when the FPRP values were less than 0.2.^\[[@R65]\]^ All statistical analyses were calculated using STATA version 9.0 (STATA Corporation, College Station, TX).

3. Results
==========

3.1. Characteristics of identified studies
------------------------------------------

A total of 144, 172, 12, and 15 studies were identified from PubMed, Embase, CNKI, and Wanfan databases (Fig. [1](#F1){ref-type="fig"}), respectively. In total, 309 records were removed when titles and abstracts were appraised for review articles, case reports, and meta-analyses. In addition, 5 studies^\[[@R23],[@R36],[@R40],[@R45],[@R46]\]^ were also removed because their data had been included in another 3 studies.^\[[@R18],[@R22],[@R34]\]^ Ultimately, 29 papers describing 30 case--control studies were selected (including 10,406 breast cancer patients and 10,115 controls) in this meta-analysis (Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}). Among these studies, thirteen were conducted in Caucasian populations, 5 in Asian, 3 in Indian, 1 in an African population, with 8 in mixed populations. Furthermore, there were 16 high-quality studies and 14 low-quality studies as determined by quality assessment of molecular association studies (Table [1](#T1){ref-type="table"}). Eight studies analyzed the combined effects of *GSTM1* and *GSTT1* polymorphisms among postmenopausal women, and 5 analyzed these associations among premenopausal women, as shown in Tables [4](#T4){ref-type="table"} and [5](#T5){ref-type="table"}.

![Flow diagram for identifying and including studies in the current meta-analysis.](medi-98-e14333-g002){#F1}

###### 

General characteristics of studies included in pooling gene effects.
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###### 

Genotype frequencies of the combined effects of *GSTM1* present/null and *GSTT1* present/null between breast cancer and control groups.
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###### 

Genotype frequencies of the combined effects of *GSTM1* present/null and *GSTT1* present/null between post-menopausal breast cancer and control groups.
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###### 

Genotype frequencies of the combined effects of *GSTM1* present/null and *GSTT1* present/null between pre-menopausal breast cancer and control groups.
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3.2. Quantitative synthesis
---------------------------

Significant heterogeneity was observed when all eligible studies were pooled in this meta-analysis. Hence, a random-effects model was used to pool the overall data. The pooled data yielded a statistically significant association between the combined effects of *GSTM1* and *GSTT1* polymorphisms and breast cancer risk (Table [6](#T6){ref-type="table"}) in all races; respective OR was 1.19 (95% CI: 1.03--1.36, *P* = .015, *P*~het~ \<.001, *I*^2^ = 60.7%) for *− +* versus *+ +*, 1.63 (95% CI: 1.29--2.06, *P* \<.001, *P*~het~ \<.001, *I*^2^ = 74.5%) for *− −* versus *+ +*, 1.17 (95% CI: 1.05--1.31, *P* = .005, *P*~het~ \<.001, *I*^2^ = 57.9%) for (*− +*) *+* (*+ −*) versus *+ +*, 1.27 (95% CI: 1.12--1.44, *P* \<.001, *P*~het~ \<.001, *I*^2^ = 69.2%) for (*− +*) *+* (*+ −*) + (*− −*) versus *+ +*, and 1.39 (95% CI: 1.17--1.66, *P* \<.001, *P*~het~ \<.001, *I*^2^ = 66.0%) for *− −* versus (*− +*) *+* (*+ −*) + (*+ +*). Subgroup analyses were also performed by ethnicity, source of controls, matching, and menopausal status.

###### 

Pooled results of the combined effects of *GSTM1* present/null and *GSTT1* present/null on breast cancer risk and FPRP test.
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First of all, we analyzed subgroups by ethnicity (Table [6](#T6){ref-type="table"}). Pooling data from Caucasians provided evidence of increased breast cancer risk; OR was 1.93 (95% CI: 1.31--2.83, *P* = .001, *P*~het~ = .001, *I*^2^ = 67.2%) for *− −* versus *+ +*, 1.36 (95% CI: 1.10--1.68, *P* = .005, *P*~het~ \<.001, *I*^2^ = 71.1%) for (*− +*) *+* (*+ −*) + (*− −*) versus *+ +*, and 1.61 (95% CI: 1.22--2.12, *P* = .001, *P*~het~ = .037, *I*^2^ = 46.7%, Fig. [2](#F2){ref-type="fig"}) for *− −* versus (*− +*) *+* (*+ −*) + (*+ +*). Pooling data from Indian populations also showed a statistically significant elevated breast cancer risk; OR was 1.70 (95% CI: 1.09--2.64, *P* = .019, *P*~het~ = .120, *I*^2^ = 52.9%) for *− +* versus *+ +*, 1.48 (95% CI: 1.19--1.84, *P* \<.005, *P*~het~ = .204, *I*^2^ = 37.1%) for (*− +*) *+* (*+ −*) versus *+ +*, and 1.54 (95% CI: 1.02--2.32, *P* = .040, *P*~het~ = .082, *I*^2^ = 60.0%) for (*− +*) *+* (*+ −*) + (*− −*) versus *+ +.* No significant association was found between the combined effects of *GSTM1* and *GSTT1* polymorphisms and breast cancer risk in Asian populations.

![Forest plot for the association between the combined effects of GSTM1 and GSTT1 polymorphisms and breast cancer risk in Caucasians (− − vs (− +) + (+ −) + (+ +)). + − = *GSTM1* present/*GSTT1* null, − + = *GSTM1* null/*GSTT1* present, − − = *GSTM1* null/*GSTT1* null, + + = *GSTM1* present/*GSTT1* present, GSTM1 = glutathione S-transferase M1, GSTT1 = glutathione S-transferase T1.](medi-98-e14333-g008){#F2}

Then, subgroups were analyzed by the source of controls (Table [6](#T6){ref-type="table"}). A statistically significant association was also shown in the population-based (PB) studies (*− −* vs *+ +*: OR = 1.40, 95% CI = 1.08--1.82, *P* = .011, *P*~het~ = .003, *I*^2^ = 65.5%, (*− +*) *+* (*+ −*) + (*− −*) vs *+ +*: OR = 1.23, 95% CI = 1.04--1.45, *P* = .015, *P*~het~ \<.001, *I*^2^ = 73.7%, *− −* vs (*− +*) *+* (*+ −*) + (*+ +*): OR = 1.22, 95% CI = 1.01--1.49, *P* = .044, *P*~het~ = .021, *I*^2^ = 54.0%) and no PB studies (− + vs + +: OR = 1.18, 95% CI = 1.01--1.38, *P* = .038, *P*~het~ = .029, *I*^2^ = 46.4%, (*− +*) *+* (*+ −*) + (*− −*) vs *+ +*: OR = 1.32, 95% CI = 1.09--1.61, *P* = .006, *P*~het~ \<.001, *I*^2^ = 67.9%, *− −* vs (*− +*) *+* (*+ −*) + (*+ +*): OR = 1.59, 95% CI = 1.20--2.11, *P* = .001, *P*~het~ \<.001, *I*^2^ = 70.6%).

In addition, we also performed subgroup analysis by matching (Table [6](#T6){ref-type="table"}). A statistically significant increased breast cancer risk was yielded in the studies of matching (*− −* vs *+ +*: OR = 1.30, 95% CI = 1.07--1.56, *P* = .007, *P*~het~ = .076, *I*^2^ = 39.7%, *− −* vs (*− +*) *+* (*+ −*) + (*+ +*): OR = 1.21, 95% CI = 1.03--1.44, *P* = .024, *P*~het~ = .031, *I*^2^ = 44.0%) and no matching (*− +* vs *+ +*: OR = 1.47, 95% CI = 1.07--2.01, *P* = .018, *P*~het~ \<.001, *I*^2^ = 74.8%, (*− +*) *+* (*+ −*) vs *+ +*: OR = 1.35, 95% CI = 1.09--1.67, *P* = .006, *P*~het~ \<.001, *I*^2^ = 71.2%).

Last, analysis of subgroups on the basis of menopausal status (Table [6](#T6){ref-type="table"}) showed that the increased breast cancer risk was found in postmenopausal women (*− −* vs *+ +*: OR = 1.49, 95% CI = 1.14--1.94, *P* = .004, *P*~het~ = .498, *I*^2^ = 0.0%, *− −* vs (*− +*) *+* (*+ −*) + (*+ +*): OR = 1.25, 95% CI = 1.02--1.53, *P* = .030, *P*~het~ = .247, *I*^2^ = 23.9%).

3.3. Heterogeneity and sensitivity analyses
-------------------------------------------

Significant heterogeneity was detected in this meta-analysis (Table [6](#T6){ref-type="table"}). Source of heterogeneity was assessed on the basis of ethnicity, source of controls, matching, sample size, and quality score using a meta-regression analysis. The results demonstrated that sample size (*+ −* vs *+ +*: *P* = .023, *− +* vs *+ +*: *P* = .006, *− −* vs *+ +*: *P* = .004, (*− +*) *+* (*+ −*) vs *+ +*: *P* = .001) and matching (*− +* vs *+ +*: *P* = .023) were sources of heterogeneity in several genetic models.

Sensitivity analysis was carried out to assess the robustness of results in this meta-analysis. Table [7](#T7){ref-type="table"} lists the results of sensitivity analysis. The results are stable when a single study was removed each time (Fig. [3](#F3){ref-type="fig"}). However, the results changed in overall population when the studies of sample size **\<**200 were excluded (*− +* vs *+ +*: OR = 1.10, 95% CI = 0.97**--**1.25, (*− +*) *+* (*+ −*) vs *+ +*: OR = 1.09, 95% CI = 0.99**--**1.19). The results also changed in overall population when the studies of low-quality were excluded (*− +* vs *+ +*: OR = 1.19, 95% CI = 0.99**--**1.43, (*− +*) *+* (*+ −*) vs *+ +*: OR = 1.16, 95% CI = 0.99**--**1.36). Last, significantly increased breast cancer risk was found when the studies only included with high-quality, matching, and genotyping examination performed bindly or with quality control (*− −* vs *+ +*: OR = 1.27, 95% CI = 1.02--1.59, *P* = .032, *P*~het~ = .038, *I*^2^ = 53.0%).

###### 

The results of sensitivity analysis and FPRP test in this meta-analysis.
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![Sensitive analysis between the combined effects of GSTM1 and GSTT1 polymorphisms and breast cancer risk in overall population ((− +) + (+ −) + (− −) vs + +). + − = *GSTM1* present/*GSTT1* null, − + = *GSTM1* null/*GSTT1* present, − − = *GSTM1* null/*GSTT1* null, + + = *GSTM1* present/*GSTT1* present, GSTM1 = glutathione S-transferase M1, GSTT1 = glutathione S-transferase T1.](medi-98-e14333-g010){#F3}

3.4. Publication bias
---------------------

Publication bias was detected using the Begg funnel plot and Egger regression asymmetry test. The shapes of Begg funnel plots (figure not shown) and the results of Egger regression asymmetry test (*− +* vs *+ +*: *P* = .049, *− −* vs *+ +*: *P* \<.001, (*+ −*) + (*− +*) vs (*+ +*): *P* = .004, (*− +*) *+* (*+ −*) + (*− −*) vs *+ +: P* = .002, *− −* vs (*− +*) *+* (*+ −*) + (*+ +*): *P* = .001) suggested that evidence of publication bias was observed in this meta-analysis. The funnel plots of the nonparametric "trim and fill" method are listed in Figure [4](#F4){ref-type="fig"}. The results were changed using the nonparametric trim and fill method in the following 4 genetic models (*− +* vs *+ +* : OR = 1.02, 95% CI = 0.86--1.20, *− −* vs *+ +*: OR = 1.12, 95% CI = 0.88--1.44, (*+ −*) + (*− +*) vs (*+ +*): OR = 1.12, 95% CI = 0.88--1.44, *− −* vs (*− +*) *+* (*+ −*) + (*+ +*): OR = 1.13, 95% CI = 0.93--1.35) in the overall meta-analysis.

!["Trim and fill" plots for the publication bias evaluation between the combined effects of GSTM1 and GSTT1 polymorphisms and breast cancer risk (− − vs (− +) + (+ −) + (+ +)). + − = *GSTM1* present/*GSTT1* null, − + = *GSTM1* null/*GSTT1* present, − − = *GSTM1* null/*GSTT1* null, + + = *GSTM1* present/*GSTT1* present, GSTM1 = glutathione S-transferase M1, GSTT1 = glutathione S-transferase T1.](medi-98-e14333-g011){#F4}

3.5. FPRP test results
----------------------

Statistically significant associations were further investigated on the basis of an FPRP test (Tables [6](#T6){ref-type="table"} and [7](#T7){ref-type="table"}). For a pre-specified prior probability of 0.001, the results were only considered noteworthy in overall pooled analysis (FPRP = 0.150 for *− −* vs *+ +* and FPRP = 0.162 for (*− +*) *+* (*+ −*) + (*− −*) vs *+ +*, Table [6](#T6){ref-type="table"}). However, none of the results were considered noteworthy, especially in the results of sensitivity analysis (Table [7](#T7){ref-type="table"}).

4. Discussion
=============

We performed a meta-analysis to assess the association between the combined effects of *GSTM1* and *GSTT1* polymorphisms on breast cancer risk, including 10,406 breast cancer patients and 10,115 controls. To our knowledge, this is the first meta-analysis to explore whether there was an association on this issue.

The pooled data from all eligible studies yielded an association between the combined effects of *GSTM1* and *GSTT1* polymorphisms and breast cancer risk. In addition, statistically significant increased breast cancer risk was also found in several subgroups, such as Caucasians, Indians, postmenopausal women, and so on, as shown in Table [6](#T6){ref-type="table"}. The pooled data were analyzed using 6 different genetic models in this study. Under the circumstances, the *P* value must be adjusted to explain the multiple comparisons.^\[[@R66]\]^ However, when *P* values were adjusted according to the FPRP method, none of the results in this meta-analysis were considered noteworthy, except the overall pooled analysis on the basis of a pre-specified prior probability of 0.001. Further, there were only 12 studies in which genotyping examination was performed blindly or with quality control. There were 18 studies that were age-matched in cases and controls, but bias may exist in the non-matched studies. Hence, we further performed a sensitivity analysis restricted to studies that only included high-quality articles, matching, and genotyping examination performed blindly or with quality control. The pooled results were not still considered noteworthy by FPRP methods. This was an attempt to avoid random errors and confounding bias that sometimes distorted the results of molecular epidemiological studies.^\[[@R67]--[@R69]\]^ Overall, the results of the present meta-analysis are more close to real value. Based on biochemical properties described for *GSTM1* and *GSTT1* polymorphisms, we expected that the combined effects of the 2 genes were associated with risk of breast cancer risk in all races. However, a significantly increased breast cancer risk may most likely be from false-positive results. Therefore, future studies should be based on sample sizes well-powered and attention needs to be paid to study design to further identify our findings.

There was significant heterogeneity in this meta-analysis. A meta-regression analysis was performed to explore the source of heterogeneity. We found sample size have contributed to the heterogeneity. In addition, evidence of publication bias was observed in this work (Fig. [4](#F4){ref-type="fig"} indicates that bias is from small-size studies). therefore, the potential source of type I error (elevation of false-positive results) may be based on publication bias in this study.^\[[@R70]\]^ Moreover, some small sample studies may be easier to accept if there was a positive report as they tend to yield false-positive results because they may be not rigorous and are often of low-quality. Furthermore, the results were also changed in overall analysis when we used the nonparametric trim and fill method. Random error and bias were common in these studies with small sample sizes, and the results were unreliable, especially in molecular epidemiological studies.^\[[@R71]\]^ In addition, research indicated that the absence of SNPs is a frequent occurrence in tumor cells.^\[[@R72]\]^ Hence, data from studies of genetic polymorphisms should be more reliable when DNA was isolated from blood cell rather than tumor cells.

There are some limitations in this meta-analysis. First, only published articles were selected in this study. Second, we did not uniformly define the controls. There were controls of 12 studies from healthy women, 11 studies from cancer-free women, 4 studies from cancer-free patients, and 3 studies with undefined controls. Hence, non-differential misclassification bias was possible exist. Third, we did not consider whether the genotype distribution in the controls was in Hardy--Weinberg equilibrium (HWE). Under normal circumstances, the HWE in the meta-analysis of genetic polymorphisms must be calculated to assess the quality, genotyping errors, and selection bias in the study.^\[[@R73],[@R74]\]^ However, we cannot calculate or extract the relevant data in the original studies. Fourth, no data were extracted on other risk factors, such as hormonal readiness, obesity, smoking, and so on. This study has also several strengths. First, a meta-analysis can increase the statistical power more than any single study. Second, we used the FPRP value to explore the false-positive results. Third, we performed an important sensitivity analysis, a dataset was used that the studies with high-quality, matching, and genotyping examination performed bindly or with quality control were only included.

After more than 10 years of extensive research on this issue, our findings should be interpreted with caution and indicate that an increased breast cancer risk may most likely result from false-positive results, rather than from true associations or biological factors on the combined effects of *GSTM1* and *GSTT1.* Future studies should be based on sample sizes well-powered and attention needs to be paid to study design to further identify this issue.
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